FDA and Prescription Drugs

The FDA has approved Eli Lilly’s oral GLP‑1 obesity pill, orforglipron (brand name Foundayo), in a 50‑day expedited review; clinical trial data showed a mean ~11.2% weight loss (≈25 lbs) at the highest dose over more than 16 months versus ~2.1% for placebo, with higher GI‑related discontinuations and a thyroid‑tumor/cancer warning. Foundayo will be sold through the Trump administration’s TrumpRx pricing platform (and Lilly’s channels), with coupons and list pricing roughly $149–$349 per month for uninsured patients and expected out‑of‑pocket costs around $25 for privately insured and about $50 for Medicare beneficiaries; shipments could begin April 6, and the pill can be taken without fasting or timing restrictions unlike oral Wegovy.